ScripChinese biotechs are racing to push back the frontiers of combination therapies for antibody-drug conjugates (ADCs), progressing multiple assets into mid-stage clinical development. Beyond the validat
ScripThere were fireworks ahead of the 4th of July festivities over the pharma sector as analysts weighed in on the rumors that a multi-billion dollar deal is in the offing between AstraZeneca and Summit T
ScripBristol Myers Squibb is following Merck & Co. and Pfizer by buying into the bispecific PD-L1xVEGF-targeting mechanism for cancer, announcing on June 2 that it will pay $1.5bn up front to BioNTech
ScripSummit Therapeutics and Akeso delivered mixed results from the first multi-regional Phase III study of ivonescimab, the companies’ PD-1/VEGF-targeting immunotherapy, in non-small cell lung cancer (NSC